Effectiveness in clinical practice of incretin-based therapies used for the treatment of type 2 diabetes: Results from a national, retrospective, UK case-note survey;Efficacite en pratique clinique courante des incretino-mimetiques dans le traitement du diabete de type 2 : Resultats d'une enquete nationale retrospective au Royaume-Uni

Medecine des Maladies Metaboliques

Volumn 8, Issue 2, 2014, Pages 177-183

  Evans, M ^a   McEwan, P ^b   O'Shea, R ^c   George, L ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Clinical effectiveness; Incretin based therapies; Recommendations; Routine clinical practice; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LIRAGLUTIDE;

ARTICLE; CLINICAL PRACTICE; HEALTH SURVEY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; RETROSPECTIVE STUDY; UNITED KINGDOM;

EID: 84907353296     PISSN: 19572557     EISSN: 22148477     Source Type: Journal    
DOI: 10.1016/S1957-2557(14)70732-1     Document Type: Article

References (10)

1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes : systematic review and meta-analysis. JAMA 2007;298:194-206.
2. Pratley RE, Nauck M, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin : a 26-week, randomised, parallelgroup, open-label trial. Lancet 2010;375:1447-56 [Erratum in : Lancet 2010;376:234].
3. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes : a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407.
4. Berg JK, Shenouda SK, Heilmann CR, et al. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures : a randomized, double-blind, crossover study. Diabetes Obes Metab 2011;13:982-9.
5. NHS. National Institute for Health and Clinical Excellence (NICE) http://pathways.nice.org.uk/pathways/diabetes. accede le 02/05/2013.
6. Buse JB, Rosenstock J, Sesti G, et al ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
7. Evans M, McEwan P, O'Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther 2012;4:27-40.
8. Gerich J. DPP-4 inhibitors : what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-40.
9. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-20.
10. Davies M, Pratley R, Hammer M, et al. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011;28:333-7.